Related Experiment Videos
Parenteral hydralazine revisited
D R Powers1, P J Papadakos, J D Wallin
1Department of Internal Medicine, Louisiana State University Medical Center at New Orleans, 70112, USA.
The Journal of Emergency Medicine
|April 16, 1998
Summary
Parenteral hydralazine remains a preferred vasodilator for severe preeclampsia and other hypertensive emergencies. Its efficacy and pharmacoeconomic potential are highlighted compared to other antihypertensive agents.
Area of Science:
- Pharmacology
- Clinical Medicine
- Drug Development
Background:
- Hydralazine is a vasodilator with a long history of use.
- Understanding its pharmacology and administration is crucial for effective treatment.
Purpose of the Study:
- To review the historical development and applications of hydralazine.
- To emphasize the parenteral use of hydralazine in hypertensive emergencies.
- To compare hydralazine's efficacy and cost-effectiveness with other antihypertensives.
Main Methods:
- Literature review of historical data.
- Pharmacological and pharmacokinetic analysis.
- Clinical efficacy and pharmacoeconomic comparisons.
Main Results:
- Parenteral hydralazine is the preferred treatment for severe preeclampsia.
- Hydralazine demonstrates efficacy in other forms of accelerated hypertension.
- Hydralazine presents favorable pharmacoeconomic potential.
Conclusions:
- Parenteral hydralazine is a valuable and cost-effective option for managing severe hypertension.
- Further consideration of hydralazine in various hypertensive conditions is warranted.